Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
- Status
- WITHDRAWN
- Phase
- PHASE1
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
- Status
- RECRUITING
- Phase
- PHASE3
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- N/A
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- N/A
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety and Tolerability of EP0042
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Copanlisib Plus Venetoclax in R/R DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
- Status
- RECRUITING
- Phase
- PHASE2
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2